| | | |

Many Elderly Mesothelioma Patients Get No Treatment

hands of elderly mesothelioma patients

The majority of elderly mesothelioma patients are observed rather than treated and this can have a negative impact on their survival.

That is the finding of a new study published in the Annals of Surgical Oncology.

The study included more than 4,500 mesothelioma patients. Less than a quarter of these patients received any treatment for their mesothelioma. As a result, most of these patients lived less than six months.

Treatment Options for Elderly Mesothelioma Patients

Exposure to asbestos causes pleural mesothelioma. It can take decades after exposure for mesothelioma symptoms to occur. The median age for a malignant pleural mesothelioma diagnosis is 72.

The older a patient is at diagnosis, the more likely they are to have other health problems. These “comorbidities” impact what mesothelioma treatment elderly mesothelioma patients can or should have.

Seniors with many other health problems might not be good candidates for surgery. Others might not be able to tolerate the stress of chemotherapy.

Observation is the Most Common “Treatment”

To conduct the new study, researchers searched the National Cancer Database for newly-diagnosed elderly mesothelioma patients who were 80 or older.

A combination of surgery and chemotherapy produces the best mesothelioma survival results for the right patients. But the study found that only two percent of the over-80 patients got this treatment.

For patients who cannot tolerate surgery (or have non-epithelioid mesothelioma) chemotherapy alone is the recommended route. Twenty-two percent of the elderly mesothelioma patients received chemotherapy.

The majority of elderly mesothelioma patients (63%) were simply “observed” by their physicians. The patients who received only observation had a median survival of 4.1 months.

In contrast, the median survival of the surgery + chemotherapy group was 12.2 months. Those who had only chemotherapy had a median survival of 9.5 months.

Elderly Mesothelioma Patients Present a Challenge

The numbers do not tell the full story. Elderly mesothelioma patients can be especially challenging to treat. Even though surgery and chemotherapy typically yield the best mesothelioma survival results, the combination is also the most risky. This is especially true for older patients.

Eleven percent of study subjects who did have surgery died within a month. Nearly 30 percent died within three months. The researchers say the key to the best outcomes for elderly mesothelioma patients is careful patient selection.

Study author Dr. Vivek Verma of Allegheny General Hospital in Pittsburgh concludes, “Although highly selected surgery/chemotherapy patients were associated with the longest OS [overall survival], given the high biases in database studies and high perioperative mortality rates, careful patient selection for combined modality approaches in this population is imperative.”

Source:

Verma, V, et al, “Management of Malignant Pleural Mesothelioma in the Elderly Population”, April 22, 2019, Annals of Surgical Oncology, Epub ahead of print, https://link.springer.com/article/10.1245%2Fs10434-019-07351-6

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…